Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.

IoT and UAV Integration in 5G Hybrid Terrestrial-Satellite Networks.

Marchese M, Moheddine A, Patrone F.

Sensors (Basel). 2019 Aug 26;19(17). pii: E3704. doi: 10.3390/s19173704. Review.

2.

Chylothorax as Rare Manifestation of Pleural Involvement in Waldenström Macroglobulinemia: Mechanisms and Management.

Leoncini G, Campisi CC, Fraternali Orcioni G, Patrone F, Ferrando F, Campisi C.

Lymphology. 2016 Dec;49(4):210-17.

PMID:
29908554
3.

Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial.

Castagnino N, Maffei M, Tortolina L, Zoppoli G, Piras D, Nencioni A, Moran E, Ballestrero A, Patrone F, Parodi S.

Wiley Interdiscip Rev Syst Biol Med. 2016 Jul;8(4):314-36. doi: 10.1002/wsbm.1342. Epub 2016 May 30. Review.

4.

Systems Medicine in Oncology: Signaling Network Modeling and New-Generation Decision-Support Systems.

Parodi S, Riccardi G, Castagnino N, Tortolina L, Maffei M, Zoppoli G, Nencioni A, Ballestrero A, Patrone F.

Methods Mol Biol. 2016;1386:181-219. doi: 10.1007/978-1-4939-3283-2_10. Review.

PMID:
26677185
5.

APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells.

Cagnetta A, Caffa I, Acharya C, Soncini D, Acharya P, Adamia S, Pierri I, Bergamaschi M, Garuti A, Fraternali G, Mastracci L, Provenzani A, Zucal C, Damonte G, Salis A, Montecucco F, Patrone F, Ballestrero A, Bruzzone S, Gobbi M, Nencioni A, Cea M.

Clin Cancer Res. 2015 Sep 1;21(17):3934-45. doi: 10.1158/1078-0432.CCR-14-3023. Epub 2015 May 11.

6.

Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies.

Tortolina L, Duffy DJ, Maffei M, Castagnino N, Carmody AM, Kolch W, Kholodenko BN, De Ambrosi C, Barla A, Biganzoli EM, Nencioni A, Patrone F, Ballestrero A, Zoppoli G, Verri A, Parodi S.

Oncotarget. 2015 Mar 10;6(7):5041-58.

7.

Sequential dose-dense 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel in patients with early breast cancer with four or more positive lymph nodes.

Murialdo R, Gallo M, Boy D, Zoppoli G, Tixi L, Gonella R, Ballestrero A, Patrone F.

Tumori. 2014 Mar-Apr;100(2):128-35. doi: 10.1700/1491.16393.

PMID:
24852855
8.

Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics.

Cagnetta A, Adamia S, Acharya C, Patrone F, Miglino M, Nencioni A, Gobbi M, Cea M.

Leuk Res. 2014 Jun;38(6):649-59. doi: 10.1016/j.leukres.2014.03.006. Epub 2014 Mar 18. Review.

PMID:
24726781
9.

Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice.

Nencioni A, da Silva RF, Fraga-Silva RA, Steffens S, Fabre M, Bauer I, Caffa I, Magnone M, Sociali G, Quercioli A, Pelli G, Lenglet S, Galan K, Burger F, Vázquez Calvo S, Bertolotto M, Bruzzone S, Ballestrero A, Patrone F, Dallegri F, Santos RA, Stergiopulos N, Mach F, Vuilleumier N, Montecucco F.

Thromb Haemost. 2014 Feb;111(2):308-22. doi: 10.1160/TH13-07-0531. Epub 2013 Nov 7.

PMID:
24196571
10.

Autophagy in blood cancers: biological role and therapeutic implications.

Nencioni A, Cea M, Montecucco F, Longo VD, Patrone F, Carella AM, Holyoake TL, Helgason GV.

Haematologica. 2013 Sep;98(9):1335-43. doi: 10.3324/haematol.2012.079061. Review.

11.

Chronic myeloid leukemia: reaching for the cure.

Nencioni A, Cea M, Montecucco F, Gobbi M, Patrone F.

Curr Cancer Drug Targets. 2013 Sep;13(7):709-10. No abstract available.

PMID:
23957630
12.

Evaluating treatment response of chronic myeloid leukemia: emerging science and technology.

Cagnetta A, Garuti A, Marani C, Cea M, Miglino M, Rocco I, Palermo C, Fugazza G, Cirmena G, Colombo N, Grasso R, Nencioni A, Gobbi M, Patrone F.

Curr Cancer Drug Targets. 2013 Sep;13(7):779-90. Review.

PMID:
23906053
13.

New insights into biology of chronic myeloid leukemia: implications in therapy.

Cea M, Cagnetta A, Nencioni A, Gobbi M, Patrone F.

Curr Cancer Drug Targets. 2013 Sep;13(7):711-23. Review.

PMID:
23906052
14.

Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.

Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Zhong MY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC.

Blood. 2013 Aug 15;122(7):1243-55. doi: 10.1182/blood-2013-02-483511. Epub 2013 Jul 3.

15.

Parameter space exploration within dynamic simulations of signaling networks.

De Ambrosi C, Barla A, Tortolina L, Castagnino N, Pesenti R, Verri A, Ballestrero A, Patrone F, Parodi S.

Math Biosci Eng. 2013 Feb;10(1):103-20. doi: 10.3934/mbe.2013.10.103.

16.

Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells.

Cea M, Cagnetta A, Patrone F, Nencioni A, Gobbi M, Anderson KC.

Autophagy. 2013 Mar;9(3):410-2.

17.

The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses.

Bauer I, Grozio A, Lasigliè D, Basile G, Sturla L, Magnone M, Sociali G, Soncini D, Caffa I, Poggi A, Zoppoli G, Cea M, Feldmann G, Mostoslavsky R, Ballestrero A, Patrone F, Bruzzone S, Nencioni A.

J Biol Chem. 2012 Nov 30;287(49):40924-37. doi: 10.1074/jbc.M112.405837. Epub 2012 Oct 18.

18.

New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.

Cea M, Cagnetta A, Gobbi M, Patrone F, Richardson PG, Hideshima T, Anderson KC.

Curr Pharm Des. 2013;19(4):734-44. Review.

19.

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.

Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC.

Blood. 2012 Oct 25;120(17):3519-29. doi: 10.1182/blood-2012-03-416776. Epub 2012 Sep 5.

20.

Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status.

Cea M, Cagnetta A, Cirmena G, Garuti A, Rocco I, Palermo C, Pierri I, Reverberi D, Nencioni A, Ballestrero A, Gobbi M, Carella AM, Patrone F.

Leuk Lymphoma. 2013 Feb;54(2):342-52. doi: 10.3109/10428194.2012.708752. Epub 2012 Sep 5.

PMID:
22762548
21.

Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.

Moran E, Carbone F, Augusti V, Patrone F, Ballestrero A, Nencioni A.

Semin Hematol. 2012 Jul;49(3):270-6. doi: 10.1053/j.seminhematol.2012.04.004. Review.

PMID:
22726551
22.

Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction.

Montecucco F, Bauer I, Braunersreuther V, Bruzzone S, Akhmedov A, Lüscher TF, Speer T, Poggi A, Mannino E, Pelli G, Galan K, Bertolotto M, Lenglet S, Garuti A, Montessuit C, Lerch R, Pellieux C, Vuilleumier N, Dallegri F, Mage J, Sebastian C, Mostoslavsky R, Gayet-Ageron A, Patrone F, Mach F, Nencioni A.

Antioxid Redox Signal. 2013 Feb 20;18(6):630-41. doi: 10.1089/ars.2011.4487. Epub 2012 May 14.

23.

Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond.

Ballestrero A, Garuti A, Cirmena G, Rocco I, Palermo C, Nencioni A, Scabini S, Zoppoli G, Parodi S, Patrone F.

Curr Cancer Drug Targets. 2012 May;12(4):316-28. Review.

PMID:
22385512
24.

A multi-scale approach to colorectal cancer: from a biochemical- interaction signaling-network level, to multi-cellular dynamics of malignant transformation. Interplay with mutations and onco-protein inhibitor drugs.

Tortolina L, Castagnino N, De Ambrosi C, Moran E, Patrone F, Ballestrero A, Parodi S.

Curr Cancer Drug Targets. 2012 May;12(4):339-55. Review.

PMID:
22385511
25.

Role of angiogenesis inhibitors in colorectal cancer: sensitive and insensitive tumors.

Bagnasco L, Piras D, Parodi S, Bauer I, Zoppoli G, Patrone F, Ballestrero A.

Curr Cancer Drug Targets. 2012 May;12(4):303-15. Review.

PMID:
22385510
26.

Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer.

Soncini D, Caffa I, Patrone F, Ballestrero A, Nencioni A.

Curr Cancer Drug Targets. 2012 May;12(4):329-38. Review.

PMID:
22385509
27.

Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols.

Bello C, Dal Bello G, Cea M, Nahimana A, Aubry D, Garuti A, Motta G, Moran E, Fruscione F, Pronzato P, Grossi F, Patrone F, Ballestrero A, Dupuis M, Sordat B, Zimmermann K, Loretan J, Wartmann M, Duchosal MA, Nencioni A, Vogel P.

Bioorg Med Chem. 2011 Dec 15;19(24):7720-7. doi: 10.1016/j.bmc.2011.07.053. Epub 2011 Jul 30.

PMID:
22079865
28.

Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells.

Cea M, Soncini D, Fruscione F, Raffaghello L, Garuti A, Emionite L, Moran E, Magnone M, Zoppoli G, Reverberi D, Caffa I, Salis A, Cagnetta A, Bergamaschi M, Casciaro S, Pierri I, Damonte G, Ansaldi F, Gobbi M, Pistoia V, Ballestrero A, Patrone F, Bruzzone S, Nencioni A.

PLoS One. 2011;6(7):e22739. doi: 10.1371/journal.pone.0022739. Epub 2011 Jul 27.

29.

Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma.

Motta G, Cea M, Carbone F, Augusti V, Moran E, Patrone F, Nencioni A.

J BUON. 2011 Jan-Mar;16(1):9-15. Review.

30.

Using coalitional games on biological networks to measure centrality and power of genes.

Moretti S, Fragnelli V, Patrone F, Bonassi S.

Bioinformatics. 2010 Nov 1;26(21):2721-30. doi: 10.1093/bioinformatics/btq508. Epub 2010 Sep 3.

PMID:
20817743
31.

Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.

Zoppoli G, Cea M, Soncini D, Fruscione F, Rudner J, Moran E, Caffa I, Bedognetti D, Motta G, Ghio R, Ferrando F, Ballestrero A, Parodi S, Belka C, Patrone F, Bruzzone S, Nencioni A.

Exp Hematol. 2010 Nov;38(11):979-88. doi: 10.1016/j.exphem.2010.07.013. Epub 2010 Aug 7.

PMID:
20696207
32.

A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.

Cea M, Cirmena G, Garuti A, Rocco I, Palermo C, Cagnetta A, Moran E, Colombo N, Grasso R, Fugazza G, Gobbi M, Nencioni A, Ballestrero A, Patrone F.

Leuk Res. 2010 Sep;34(9):e240-2. doi: 10.1016/j.leukres.2010.03.036. Epub 2010 May 5. No abstract available.

PMID:
20447687
33.

Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies.

Bello C, Cea M, Dal Bello G, Garuti A, Rocco I, Cirmena G, Moran E, Nahimana A, Duchosal MA, Fruscione F, Pronzato P, Grossi F, Patrone F, Ballestrero A, Dupuis M, Sordat B, Nencioni A, Vogel P.

Bioorg Med Chem. 2010 May 1;18(9):3320-34. doi: 10.1016/j.bmc.2010.03.009. Epub 2010 Mar 9.

PMID:
20346684
34.

Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more.

Cea M, Cagnetta A, Garuti A, Cirmena G, Rocco I, Moran E, Grillo V, Ballestrero A, Patrone F, Nencioni A.

J BUON. 2009 Oct-Dec;14(4):565-73. Review.

35.

Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.

Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, Soncini D, Moran E, Zoppoli G, Pistoia V, Patrone F, Ballestrero A.

PLoS One. 2010 Feb 2;5(2):e9024. doi: 10.1371/journal.pone.0009024.

36.

Ras-induced resistance to lapatinib is overcome by MEK inhibition.

Zoppoli G, Moran E, Soncini D, Cea M, Garuti A, Rocco I, Cirmena G, Grillo V, Bagnasco L, Icardi G, Ansaldi F, Parodi S, Patrone F, Ballestrero A, Nencioni A.

Curr Cancer Drug Targets. 2010 Mar;10(2):168-75.

PMID:
20088787
37.

Incentive compatibility in kidney exchange problems.

Villa S, Patrone F.

Health Care Manag Sci. 2009 Dec;12(4):351-62.

PMID:
20058525
38.

Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.

Motta G, Cea M, Moran E, Carbone F, Augusti V, Patrone F, Nencioni A.

Clin Dev Immunol. 2010;2010:428253. doi: 10.1155/2010/428253. Epub 2011 Mar 6. Review.

39.

Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia.

Carella AM, Garuti A, Cirmena G, Catania G, Rocco I, Palermo C, Pica G, Pierri I, Miglino M, Ballestrero A, Gobbi M, Patrone F.

Leuk Lymphoma. 2010 Feb;51(2):275-8. doi: 10.3109/10428190903503446.

PMID:
20038234
40.

Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients.

Ballestrero A, Cirmena G, Dominietto A, Garuti A, Rocco I, Cea M, Moran E, Nencioni A, Miglino M, Raiola AM, Bacigalupo A, Patrone F.

Int J Lab Hematol. 2010 Aug 1;32(4):387-91. doi: 10.1111/j.1751-553X.2009.01198.x. Epub 2009 Nov 30.

PMID:
19968720
41.

Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.

Bruzzone S, Fruscione F, Morando S, Ferrando T, Poggi A, Garuti A, D'Urso A, Selmo M, Benvenuto F, Cea M, Zoppoli G, Moran E, Soncini D, Ballestrero A, Sordat B, Patrone F, Mostoslavsky R, Uccelli A, Nencioni A.

PLoS One. 2009 Nov 19;4(11):e7897. doi: 10.1371/journal.pone.0007897.

42.

APO866 activity in hematologic malignancies: a preclinical in vitro study.

Cea M, Zoppoli G, Bruzzone S, Fruscione F, Moran E, Garuti A, Rocco I, Cirmena G, Casciaro S, Olcese F, Pierri I, Cagnetta A, Ferrando F, Ghio R, Gobbi M, Ballestrero A, Patrone F, Nencioni A.

Blood. 2009 Jun 4;113(23):6035-7; author reply 6037-8. doi: 10.1182/blood-2009-03-209213. No abstract available.

PMID:
19498032
43.

Combining Shapley value and statistics to the analysis of gene expression data in children exposed to air pollution.

Moretti S, van Leeuwen D, Gmuender H, Bonassi S, van Delft J, Kleinjans J, Patrone F, Merlo DF.

BMC Bioinformatics. 2008 Sep 2;9:361. doi: 10.1186/1471-2105-9-361.

44.

The use of dendritic cells in cancer immunotherapy.

Nencioni A, Grünebach F, Schmidt SM, Müller MR, Boy D, Patrone F, Ballestrero A, Brossart P.

Crit Rev Oncol Hematol. 2008 Mar;65(3):191-9. Epub 2007 Dec 4. Review.

PMID:
18055210
45.

Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas.

Ballestrero A, Boy D, Gonella R, Miglino M, Clavio M, Barbero V, Nencioni A, Gobbi M, Patrone F.

Ann Hematol. 2008 Jan;87(1):49-55. Epub 2007 Aug 21.

PMID:
17710398
46.

Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity.

Nencioni A, Beck J, Werth D, Grünebach F, Patrone F, Ballestrero A, Brossart P.

Clin Cancer Res. 2007 Jul 1;13(13):3933-41.

47.

The proteasome and its inhibitors in immune regulation and immune disorders.

Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P.

Crit Rev Immunol. 2006;26(6):487-98. Review.

PMID:
17341190
48.

Proteasome inhibitors: antitumor effects and beyond.

Nencioni A, Grünebach F, Patrone F, Ballestrero A, Brossart P.

Leukemia. 2007 Jan;21(1):30-6. Epub 2006 Nov 9. Review.

PMID:
17096016
49.

Actively bleeding Dieulafoy's lesion of the small bowel identified by capsule endoscopy and treated by push enteroscopy.

De Palma GD, Patrone F, Rega M, Simeoli I, Masone S, Persico G.

World J Gastroenterol. 2006 Jun 28;12(24):3936-7.

50.

Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells.

Nencioni A, Garuti A, Schwarzenberg K, Cirmena G, Dal Bello G, Rocco I, Barbieri E, Brossart P, Patrone F, Ballestrero A.

Eur J Immunol. 2006 Mar;36(3):681-9.

Supplemental Content

Loading ...
Support Center